Search

Your search keyword '"Hiebert, Brett M."' showing total 31 results
Start Over Author "Hiebert, Brett M."
31 results on '"Hiebert, Brett M."'

13. Reply to the Editor

Author

Arenson, Benjamin G., MacDonald, Lindsey A., Grocott, Hilary P., Hiebert, Brett M., and Arora, Rakesh C.

Published
2014
Full Text
View/download PDF

18. Pre-frailty and Cardiovascular Risk Profile in Middle-Aged and Older Women

Author

Boreskie, Kevin, D Scott Kehler, Costa, Eduardo Caldas, Cortez, Pedro C, Hamm, Naomi, Moffatt, Teri, Stammers, Andrew N, Kimber, Dustin E, Hiebert, Brett M., Kent, David E, Cornish, Denise E, Blewett, Heather, Nguyen, Thang, Arora, Rakesh C, Shaelyn M Strachan, Semenchuk, Brittany N, Hay, Jacqueline, Berkowitz, Ivan, and Duhamel, Todd A

Published
2018
Full Text
View/download PDF

20. Standardization of the Fried frailty phenotype improves cardiovascular disease risk discrimination

Author

Boreskie, Kevin F., primary, Kehler, D. Scott, additional, Costa, Eduardo C., additional, Hiebert, Brett M., additional, Hamm, Naomi C., additional, Moffatt, Teri L., additional, Hay, Jacqueline L., additional, Stammers, Andrew N., additional, Kimber, Dustin E., additional, Kent, David E., additional, Cornish, Denise E., additional, Arora, Rakesh C., additional, Strachan, Shaelyn M., additional, Semenchuk, Brittany N., additional, and Duhamel, Todd A., additional

Published
2019
Full Text
View/download PDF

21. Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study.

Author

Hiebert, Brett M., Janzen, Bryan W., Sanjanwala, Rohan M., Ong, Aldrich D., Feldman, Ross D., and Kim, Julian O.

Subjects
*PROSTATE cancer, *HEART failure, *PHARMACOEPIDEMIOLOGY, *SPIRONOLACTONE, *PROPORTIONAL hazards models, *CELL cycle regulation, *PROSTATE-specific antigen
Abstract

Aims: Aldosterone has been found to influence cancer cell growth, cell cycle regulation and cell migration, including in prostate cancer cells. Spironolactone is an aldosterone antagonist used for managing chronic heart failure (HF) with known antiandrogenic effects. We examined the effect of spironolactone exposure amongst men with HF on the incidence of prostate cancer. Methods: This retrospective cohort study utilized provincial clinical and administrative databases from the Manitoba Centre for Health Policy. Incident cases of prostate cancer were identified from the provincial cancer registry, and spironolactone exposure was quantified from pharmacare databases. A multivariable proportional hazards model was used to assess the time‐dependent impact of spironolactone exposure on prostate cancer incidence. Results: A total of 18 562 men with newly diagnosed HF from 2007 to 2015 with a median age of 72 years (interquartile range: 61–81) and a median follow‐up from HF diagnosis to prostate cancer incidence of 2.7 years (interquartile range: 1.1–4.9) were included. A time‐dependent multivariable analysis of spironolactone exposure following HF diagnosis found a reduced the risk of prostate cancer hazard ratio 0.55 (95% confidence interval 0.31–0.98, P =.043). Conclusion: Spironolactone exposure significantly reduced the incidence of prostate cancer amongst men with HF. These findings support the plausibility of aldosterone as a promoter of prostate cancer growth and development. Prospective clinical trials are warranted to further assess the role of spironolactone or other mineralocorticoid receptor antagonists as a means to prevent prostate cancer development or as an adjunctive measure to prostate cancer treatments. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. Protocol for the HAPPY Hearts study: cardiovascular screening for the early detection of future adverse cardiovascular outcomes in middle-aged and older women: a prospective, observational cohort study

Author

Boreskie, Kevin F, primary, Kehler, D Scott, additional, Costa, Eduardo C, additional, Cortez, Pedro C, additional, Berkowitz, Ivan, additional, Hamm, Naomi C, additional, Moffatt, Teri L, additional, Stammers, Andrew N, additional, Kimber, Dustin E, additional, Hiebert, Brett M, additional, Kent, David E, additional, Cornish, Denise E, additional, Blewett, Heather, additional, Nguyen, Thang, additional, Arora, Rakesh C, additional, Strachan, Shaelyn M, additional, Semenchuk, Brittany N, additional, Hay, Jacqueline L, additional, Cohn, Jay N, additional, and Duhamel, Todd A, additional

Published
2017
Full Text
View/download PDF

31. Pre-Operative Frailty Status Is Associated with Cardiac Rehabilitation Completion: A Retrospective Cohort Study.

Author

Kimber, Dustin E., Kehler, D. Scott, Lytwyn, James, Boreskie, Kevin F., Jung, Patrick, Alexander, Bryce, Hiebert, Brett M., Dubiel, Chris, Hamm, Naomi C., Stammers, Andrew N., Clarke, Mekayla, Fraser, Carly, Pedreira, Brittany, Tangri, Navdeep, Hay, Jacqueline L., Arora, Rakesh C., and Duhamel, Todd A.

Subjects
COHORT analysis, RETROSPECTIVE studies, CARDIAC surgery, REHABILITATION
Abstract

While previous investigations have demonstrated the benefit of cardiac rehabilitation (CR) on outcomes after cardiac surgery, the association between pre-operative frailty and post-operative CR completion is unclear. The purpose of this retrospective cohort study was to determine if pre-operative frailty scores impacted CR completion post-operatively and if CR completion influenced frailty scores in 114 cardiac surgery patients. Frailty was assessed with the use of the Clinical Frailty Scale (CFS), the Modified Fried Criteria (MFC), the Short Physical Performance Battery (SPPB), and the Functional Frailty Index (FFI). A Mann-Whitney test was used to compare frailty scores between CR completers and non-completers and changes in frailty scores from baseline to 1-year post-operation. CR non-completers were more frail than CR completers at pre-operative baseline based on the CFS (p = 0.01), MFC (p < 0.001), SPPB (p = 0.007), and the FFI (p < 0.001). A change in frailty scores from baseline to 1-year post-operation was not detected in either group using any of the four frailty assessments. However, greater improvements from baseline to 1-year post-operation in two MFC domains (cognitive impairment and low physical activity) and the physical domain of the FFI were found in CR completers as compared to CR non-completers. These data suggest that pre-operative frailty assessments have the potential to identify participants who are less likely to attend and complete CR. The data also suggest that frailty assessment tools need further refinement, as physical domains of frailty function appear to be more sensitive to change following CR than other domains of frailty. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results